Brian Hocum, PharmD

Director, Data Generation & Observational Studies
Bayer

Poster(s):

• (303) Real-world (RW) sequential regorafenib and trifluridine/tipiracil + bevacizumab (BEV) treatment for metastatic colorectal cancer (mCRC) in the United States (US) community oncology setting A post-hoc analysis of SEQRT2 study
  Wednesday, October 29, 2025

• (372) A retrospective cohort study examining the real-world disease progression, HCRU, and costs among patients with T2D with newly diagnosed CKD stage III or IV with and without finerenone use
  Wednesday, October 29, 2025